Login
Israel-Hamas Conflict
Airstrike
Social Media
Benjamin Netanyahu
World Cup
Aviation Accidents
Military
Donald Trump
Artificial Intelligence
Immigration and Customs Enforcement
Baseball
Education
Cryptocurrency
institutional access

You are connecting from
Lake Geneva Public Library,
please login or register to take advantage of your institution's Ground News Plan.

Published • loading... • Updated

#Incytes Retifanlimab Shows Promise in Phase 3 Trial for Anal Canal Cancer, While Financial Performance Outpaces Comp...

Summary by csimarket.com
Incyte's Advancements in Cancer Treatment: Promising Phase 3 Data for Retifanlimab and Strong Revenue Growth Amidst Competitive Challenges In the ever-evolving landscape of oncology, few developments spark as much interest as groundbreaking clinical trial results. Incyte Corporation (Nasdaq: INCY) has recently captured attention with the release of pivotal Phase 3 data for retifanlimab (trade name: Zynyz), its humanized monoclonal antibody targe…

3 Articles

All
Left
Center
Right
1
ilgiornale.itilgiornale.it
Lean Right

Phase 3 Data for Incyte Retifanximab (Zynyz®) in Patients with Anal Canal Squamous Cell Carcinoma (SCAC) Were Published in The Lancet

Phase 3 data for Incyte retifanximab (Zynyz®) in patients with anal canal squamous cell carcinoma (SCAC) were published in The Lancet

·Italy
Read Full Article
cancernetwork.comcancernetwork.com

Adding Retifanlimab to Chemo Yields Clinical Benefit in Inoperable SCAC

Results from the phase 3 POD1UM-303/InterAACT-2 trial demonstrated improved PFS and OS in patients with locally recurrent or metastatic SCAC.

Read Full Article
csimarket.comcsimarket.com

#Incytes Retifanlimab Shows Promise in Phase 3 Trial for Anal Canal Cancer, While Financial Performance Outpaces Comp...

Incyte's Advancements in Cancer Treatment: Promising Phase 3 Data for Retifanlimab and Strong Revenue Growth Amidst Competitive Challenges In the ever-evolving landscape of oncology, few developments spark as much interest as groundbreaking clinical trial results. Incyte Corporation (Nasdaq: INCY) has recently captured attention with the release of pivotal Phase 3 data for retifanlimab (trade name: Zynyz), its humanized monoclonal antibody targe…

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources lean Right
100% Right
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

ilgiornale.it broke the news in Italy on Friday, June 13, 2025.
Sources are mostly out of (0)

Similar News Topics

News
For You
SearchBlindspotLocal